Companies /Healthcare

Envista Holdings Corp

NYSE: NVST Medical Instruments & Supplies
$27.28
▼ $0.31 (−1.12%) today
Markets closed · 6:37pm ET

Q3 2025 Earnings

Reported Oct 29, 2025, 4:57pm ET · SEC source
$0.32
Beat +15.94%
EPS · est. $0.28
$669.9M
Beat +4.55%
Revenue · est. $640.8M
−0.0%
Trailing market
NVST vs S&P since report
5 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+3%+6%Oct 29Oct 30report 4:57pm ETearnings−0.7%+0.8%
0+3%+6%Oct 29Oct 30earnings−0.7%+0.8%
NVST +0.8%S&P 500 −0.7%
0+3%+6%Oct 29Oct 30report 4:57pm ETearnings−0.9%+0.8%
0+3%+6%Oct 29Oct 30earnings−0.9%+0.8%
NVST +0.8%NASDAQ −0.9%
−6%−3%0Oct 28Nov 6report 4:57pm ETearnings−2.1%−6.8%
−6%−3%0Oct 28Nov 6earnings−2.1%−6.8%
NVST −6.8%S&P 500 −2.1%
−6%−3%0Oct 28Nov 6report 4:57pm ETearnings−3.4%−6.8%
−6%−3%0Oct 28Nov 6earnings−3.4%−6.8%
NVST −6.8%NASDAQ −3.4%
+0.80%
Day of report
+1.04%
Next session
−3.28%
One week
+0.20%
30 days

S&P 500 over the same 30 days: +0.25%.

Did NVST Beat Earnings? Q3 2025 Results

Envista Holdings posted a convincing beat across the board in the third quarter of fiscal 2025, with adjusted diluted EPS of $0.32 clearing the $0.28 consensus estimate by 15.94% and revenue of $669.90 million topping expectations by 4.55% on 11.5% year-over-year growth. The primary engine behind the quarter's strength was the Specialty Products & Technologies segment, which grew total sales 13.0% to $431.50 million, while Equipment & Consumables contributed 8.7% growth to $238.40 million, together reflecting broad-based momentum across the dental portfolio. Profitability expanded sharply, with adjusted EBITDA rising 77% to $97.10 million and adjusted EBITDA margin widening 540 basis points to 14.5%. A GAAP net loss of $30.30 million, driven by a $61.20 million discrete tax charge from intercompany loan restructuring, obscured the underlying operating progress. Management responded to the quarter's performance by raising full-year core sales growth guidance to approximately 4% and tightening adjusted diluted EPS guidance to $1.10 to $1.15, though some analysts flag potential headwinds from China's next round of volume-based procurement into 2026.

Key Takeaways
  • Core sales growth of 9.4% in Q3 2025
  • All major businesses delivered positive growth
  • Spark aligners captured market share and achieved positive operating margin
  • Envista Business System (EBS) drove broad-based operational contributions
  • Specialty Products & Technologies segment posted 10.6% core sales growth
  • Adjusted EBITDA margin expanded 540 bps year-on-year to 14.5%
  • Adjusted gross margin improved to 56.1% from 52.8%

“This was another strong quarter for Envista, with core growth, adjusted EBITDA, and adjusted EPS all ahead of expectations.”

Envista CEO, on the earnings call

Forward Guidance & Outlook

Envista updated its full-year 2025 guidance, raising core sales growth expectations to approximately 4% (from 3% to 4% previously), maintaining adjusted EBITDA margin at approximately 14%, and narrowing/raising adjusted diluted EPS guidance to $1.10 to $1.15 (from $1.05 to $1.15 previously).

NVST YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$200.0M$400.0M$600.0M$601.0M$669.9MRevenue$317.4M$370.2MGross Profit$20.9M$57.5MOperating Income
$0$200.0M$400.0M$600.0MRevenueGross ProfitOperating Income

NVST Revenue by Segment

Specialty Products & Technologies$431.5M+13.0%
Equipment & Consumables$238.4M+8.7%

Figures from SEC filings and company reports. Not investment advice.